Can-Fite BioPharma Ltd. (CANF)
 NYSEAMERICAN: CANF · Real-Time Price · USD
 0.4118
 -0.0108 (-2.56%)
  At close: Nov 3, 2025, 4:00 PM EST
0.4118
 0.00 (0.00%)
  Pre-market: Nov 4, 2025, 8:00 AM EST
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K in the half year ending June 30, 2025, a decrease of -48.47%. This brings the company's revenue in the last twelve months to $560.00K, down -16.04% year-over-year. In the year 2024, Can-Fite BioPharma had annual revenue of $674.00K, down -9.29%.
Revenue (ttm) 
 $560.00K
Revenue Growth 
 -16.04%
P/S Ratio 
 28.08
Revenue / Employee 
 $112,000
Employees 
 5
Market Cap 
15.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% | 
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% | 
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% | 
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% | 
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue | 
|---|---|
| UnitedHealth Group | 435.16B | 
| Johnson & Johnson | 92.15B | 
| Merck & Co. | 64.24B | 
| AbbVie | 59.64B | 
| Eli Lilly and Company | 59.42B | 
| AstraZeneca | 56.50B | 
| Novartis AG | 56.37B | 
| Novo Nordisk | 49.11B | 
CANF News
- 2 months ago - Can-Fite Reports H1 2025 Financial Results and Clinical Update - GlobeNewsWire
 - 3 months ago - Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone - GlobeNewsWire
 - 3 months ago - Can-Fite Announces Up To $15.0 Million Public Offering - GlobeNewsWire
 - 3 months ago - Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia - GlobeNewsWire
 - 7 months ago - Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients - GlobeNewsWire
 - 7 months ago - Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares - GlobeNewsWire
 - 8 months ago - Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market - GlobeNewsWire
 - 8 months ago - Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson - GlobeNewsWire